文献速递淋巴瘤

HDAC6调控microRNA-27b抑制弥漫大B细胞淋巴瘤增殖、促进凋亡并靶向MET

HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2017-09-28

研究在HDAC6敲低弥漫大B细胞淋巴瘤(DLBCL)细胞中用NanoString nCounter检测miRNA变化,发现miR-27b升高最显著;DLBCL组织中miR-27b低表达与患者总生存差相关,强制表达miR-27b可抑制细胞活力、增殖及体内肿瘤生长;机制上HDAC6抑制通过Rel A/p65乙酰化及核转位阻断上调miR-27b,进而靶向MET抑制MET/PI3K/AKT通路。

要点

  • HDAC6敲低DLBCL细胞中miR-27b升高最显著。
  • DLBCL组织miR-27b低表达与总生存差相关。
  • miR-27b靶向MET并抑制MET/PI3K/AKT通路。

核心结论

  • miR-27b在DLBCL发展中起重要作用,并揭示HDAC6-Rel A/p65-miR-27b-MET信号通路。
  • 通过抑制HDAC6升高miR-27b可能是DLBCL治疗的有前景策略。

研究设计与样本

  • 研究在HDAC6敲低的DLBCL细胞中用NanoString nCounter检测miRNA变化,并验证DLBCL组织中miR-27b表达及与总生存的关系。
  • 体外强制表达miR-27b检测DLBCL细胞活力与增殖,体内检测肿瘤生长。

主要发现

  • HDAC6敲低DLBCL细胞中miR-27b是升高最显著的miRNA。
  • DLBCL组织中miR-27b表达降低,低表达与患者总生存差相关。
  • 强制表达miR-27b抑制DLBCL细胞体外活力和增殖,并抑制体内肿瘤生长。
  • Rel A/p65负向调控miR-27b表达,HDAC6抑制导致其乙酰化及核转位阻断,显著升高miR-27b表达。
  • miR-27b靶向MET并抑制MET/PI3K/AKT通路。

临床怎么用

  • 作者认为通过抑制HDAC6升高miR-27b可能是DLBCL治疗的有前景策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Histone deacetylase 6 (HDAC6) is frequently altered in DLBCL and inhibition of HDAC6 has potent anti-tumor effects in vitro and in vivo. We profiled miRNAs that altered in the HDAC6 knockdown DLBCL cells with NanoString nCounter assay and identified microRNA-27b (miR-27b) as the most significantly increased miRNA. We validated decreased expression of miR-27b in DLBCL tissues, and we found that low expression of miR-27b was associated with poor overall survival of patients with DLBCL. In addition, forced expression of miR-27b suppressed DLBCL cell viability and proliferation in vitro, and inhibited tumor growth in vivo. Mechanistically, Rel A/p65 is found to negatively regulate miR-27b expression, and its acetylation and block of nuclear translocalization caused by HDAC6 inhibition significantly elevates miR-27b expression. Furthermore, miR-27b targets MET and thus represses the MET/PI3K/AKT pathway. These findings highlight an important role of miR-27b in the development of DLBCL and uncover a HDAC6-Rel A/p65-miR-27b-MET signaling pathway. Elevating miR-27b through HDAC6 inhibition would be a promising strategy for DLBCL treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jia YJ, Liu ZB, Wang WG, et al. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. Leukemia. 2017. PMID: 29135973. doi:10.1038/leu.2017.299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。